FDA clears Pfizer drug for advanced kidney cancer - Wall Street Journal PDF Print
Wall Street Journal
The Food and Drug Administration approved the company's drug Inlyta as a secondary option for patients with renal cell carcinoma that hasn't responded to previous drug treatments. Renal cell carcinoma is the most common form of kidney cancer,

...

 
Share |
Copyright © 2025 Global Dialysis. All Rights Reserved.